Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 58,007	$ 62,478
Short-term restricted cash	870	1,034
Prepaid expenses and other current assets	4,211	6,344
Refundable tax credit	1,536	1,276
Total current assets	64,624	71,132
Operating lease right-of-use assets	2,866	3,331
Other assets	555	507
Total assets	68,045	74,970
Current liabilities:
Current portion of debt	258	208
Accounts payable	2,773	1,495
Accrued expenses	6,738	9,066
Operating lease liabilities — current	1,442	1,751
Total current liabilities	11,211	12,520
Debt, net of current portion	110	168
Operating lease liabilities	2,078	2,395
Other liabilities	7	16
Total liabilities	13,406	15,099
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value: 100,000,000 shares authorized; 18,998,252 and 18,266,545 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	19	18
Additional paid-in capital	274,340	267,018
Accumulated deficit	(220,652)	(208,654)
Accumulated other comprehensive income	123	165
Total stockholders’ equity attributable to Millendo Therapeutics, Inc.	53,830	58,547
Equity attributable to noncontrolling interests	809	1,324
Total stockholders’ equity	54,639	59,871
Total liabilities and stockholders’ equity	$ 68,045	$ 74,970